Aetna Launches SimplePay Health
Aetna, a CVS Health company (NYSE: CVS), has introduced SimplePay Health, a new health plan tailored for self-insured clients. This plan aims to reduce costs, enhance health outcomes, and streamline…
Category News
Read MoreAetna Launches SimplePay Health
DIA Canada Annual Meeting Focuses on Precision Regulation and Clinical Trial Advances
DIA, a global non-profit organization for life sciences professionals, will host discussions on Canada’s precision regulation initiatives, the enhancement of its clinical trial infrastructure, and international collaboration at the Canada…
Nordic Group Launches LACRIFILL® Canalicular Gel for Dry Eye at 2024 AAO
Nordic Pharma, Inc., a subsidiary of Nordic Group BV, introduced LACRIFILL Canalicular Gel, an innovative therapy for dry eye, in the U.S. this April and is showcasing it to leading…
Glaukos Reports Positive Phase 3 Results for Epioxa™, Meeting Primary Efficacy Endpoint
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on innovative therapies for glaucoma, corneal disorders, and retinal diseases, has announced positive results from the second Phase…
Celltrion Reveals Two-Year Post-Hoc Analysis Results for Subcutaneous Infliximab (CT-P13 SC) in IBD Treatment
Celltrion has announced the two-year results of dose escalation therapy with subcutaneous infliximab (CT-P13 SC) at the United European Gastroenterology (UEG) Week 2024 in Vienna. A post-hoc analysis of the…
Exelixis and Merck Collaborate on Zanzalintinib Trials for Cancer
Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, have announced a clinical development collaboration. The partnership will evaluate the investigational tyrosine kinase…
Transverse Medical Welcomes Professor Ian T. Meredith to Board of Directors
Transverse Medical, Inc., known for its POINT-GUARD™ Cerebral Embolic Protection device, is excited to announce the appointment of Ian T. Meredith, MD, to its Board of Directors. With over 35…
Melt Pharmaceuticals Completes Dosing of Final Patient in Phase 3 Study of MELT-300 for Cataract Surgery Sedation
Melt Pharmaceuticals, Inc., a clinical-stage company focused on innovative procedural sedation solutions, has announced the dosing of the last patient in its pivotal Phase 3 study of MELT-300, a non-IV,…
MiLaboratories Raises $10 Million in Series A Funding for Genomic Research
MiLaboratories, a leader in computational biology innovation, is excited to announce the successful completion of its Series A funding round, led by Madrid-based Kfund, with additional support from Speedinvest and…
Siemens Healthineers Co-Leads EU Stroke Care Improvement Project
Siemens Healthineers is collaborating with over 20 industry and public partners, including seven leading stroke hospitals, to enhance stroke management across Europe. The five-year UMBRELLA project, with a total budget…
Elevance Health’s 2025 Medicare Advantage Plans Overview
Elevance Health (NYSE: ELV) has announced its affiliated health plans will offer flexible Medicare Advantage options with personalized supplemental benefits aimed at enhancing the overall health of nearly 40.3 million…
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Rule 5635(C)(4)
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on innovative treatments for neurological diseases, announced the granting of inducement awards to three new employees. The Board’s Compensation Committee…